Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infecte...(II study of vicriviroc in a novel nucleo...),Health

Date:9/14/2009

II study of vicriviroc in a novel nucleoside-sparing regimen for first-line therapy of adult treatment-naive HIV-infected patients with R5-tropic virus only. Approximately 80-90 percent of treatment-naive patients have virus that uses the CCR5 co-receptor.(3) The study evaluates vicriviroc 30 mg once-daily in combination with ritonavir-boosted atazanavir,(4) compared to a control group receiving Truvada (emtricitabine and tenofovir disoproxil fumarate)(5) plus ritonavir-boosted atazanavir, which is a currently recommended option for first-line therapy. This novel nucleoside-sparing vicriviroc regimen is designed to provide additional options for treatment-naive patients in a once daily regimen, while preserving other drug classes for subsequent lines of treatment. The study involves 200 patients at more than 35 sites in North America, Central America, Europe and South Africa. The study is sponsored by Schering-Plough with support from Bristol-Myers Squibb.

For more information about vicriviroc clinical studies, please visit www.clinicaltrials.gov, search term: vicriviroc.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., USA, and its Web site is www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of th
'/>"/>

SOURCE Schering-Plough Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
2. Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
3. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
4. Schering-Plough Announces Results of the Early ACS Trial
5. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
6. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
7. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
8. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
9. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
10. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
11. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant